4D Pharma said it entered into a collaboration agreement with a subsidiary of Merck & Co. Inc. (MRK) to conduct a clinical trial evaluating its anti-cancer drug MRx0518 for use in tandem with a Merck therapy.
The pharmaceutical company said the phase 1 clinical trial will evaluate the effectiveness of MRx0518 in combination with cancer drug Keytruda in patients with renal, bladder and non-small cell lung cancer, as well as melanoma. The study will evaluate the safety, tolerability and preliminary clinical benefits of the drug combination, 4D pharma said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.